pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 6·1 min read
save

Salk Institute President Warns of NIH Funding Cuts While Embracing AI and Brain Research Initiatives

Jul 6, 2026·read at Endpoints ↗RegulatoryNeutral

Gerald Joyce, president of the Salk Institute, highlighted recent reductions in NIH funding and their impact on research institutions.

He said the institute is fully committing resources to artificial intelligence to accelerate discovery, especially in neuroscience.

Joyce also noted that 2026 has been designated the Year of the Brain, providing a thematic focus for collaborative projects.

He emphasized the need for diversified funding sources to sustain the institute’s mission amid budget pressures.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Salk Institute’s president on NIH cuts, ‘all in’ on AI, and the Year of the Brain”

read at Endpoints ↗
98 words · retrieved Jul 6
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 6h agoMerck's top dealmaker signals more M&A as Keytruda's patent cliff nearsEndpoints
  • 9h agoNovartis' drug delivery deal with Alteogen; More worker cuts at CellaresEndpoints
  • 9h agoPfizer shares ADC rights with Medicus; RevMed updates lung cancer dataEndpoints
  • 10h agoAbbVie claims Phase 3 win for multiple myeloma drug etentamigEndpoints
  • 11h agoHealth tech investors are looking at bigger betsEndpoints